SOPHiA GENETICS SA
SOPHNext catalyst
Alleance®
Myopia
Get an email about SOPH's next catalysts
Track SOPHiA GENETICS (SOPH) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
No other upcoming event in our data.
1 upcoming, 1 past
Alleance® Phase 3 Est. Readout
Primary completion for Alleance® trial (NCT06389110) in Myopia
SourceMarket Overview
Stock performance and key metrics
Sophia Genetics SA is a Swiss-founded data-driven medicine software company with headquarters in Rolle, Switzerland and Boston, Massachusetts, as well as offices in France. It provides genomic and radiomic, and multimodal analysis for hospitals, laboratories, and biopharma institutions.
WebsiteLucentis®
Diabetic Macular Edema
Alleance®
Myopia
half molar sodium lactate
Head Trauma
Moxifloxacin/Dexamethasone Ophthalmic Solution
Cataract Extraction
Krytantek Ofteno®
Primary Open Angle Glaucoma
PRO-148
Dry Eye
PRO-122
Primary Open Angle Glaucoma
Difluprednate
Cataract
Sodium Hyaluronate Ophthalmic Six times
Dry Eye
Sodium Hyaluronate Ophthalmic one drop
Dry Eye
Sodium Hyaluronate Ophthalmic one drop four times
Dry Eye
Nanodrop®
Dry Eye
PRO-155
Cataract
dorzolamide-timolol-brimonidine
Primary Open Angle Glaucoma
PRO-148 Ophthalmic Solution
Dry Eye Syndrome
Sodium Hyaluronate Ophthalmic
Dry Eye
PRO-157
Bacterial Conjunctivitis
Lagricel Ofteno®
Bacterial Conjunctivitis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Lucentis® | Phase 3 | Diabetic Macular Edema | - | - |
Alleance® | Phase 3 | Myopia | - | - |
half molar sodium lactate | Phase 3 | Head Trauma | - | - |
Moxifloxacin/Dexamethasone Ophthalmic Solution | Phase 3 | Cataract Extraction | - | - |
Krytantek Ofteno® | Phase 3 | Primary Open Angle Glaucoma | - | - |
PRO-148 | Phase 3 | Dry Eye | - | - |
PRO-122 | Phase 3 | Primary Open Angle Glaucoma | - | - |
Difluprednate | Phase 3 | Cataract | - | - |
Sodium Hyaluronate Ophthalmic Six times | Phase 2 | Dry Eye | - | - |
Sodium Hyaluronate Ophthalmic one drop | Phase 2 | Dry Eye | - | - |
Sodium Hyaluronate Ophthalmic one drop four times | Phase 2 | Dry Eye | - | - |
Nanodrop® | Phase 2 | Dry Eye | - | - |
PRO-155 | Phase 2 | Cataract | - | - |
dorzolamide-timolol-brimonidine | Phase 2 | Primary Open Angle Glaucoma | - | - |
PRO-148 Ophthalmic Solution | Phase 2 | Dry Eye Syndrome | - | - |
Sodium Hyaluronate Ophthalmic | Phase 2 | Dry Eye | - | - |
PRO-157 | Phase 2 | Bacterial Conjunctivitis | - | - |
Lagricel Ofteno® | Phase 2 | Bacterial Conjunctivitis | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in SOPHiA GENETICS SA's drug pipeline?→
CatalystAlert tracks 18 drug candidates in SOPHiA GENETICS SA's (SOPH) pipeline across Phase 3, Phase 2. Its lead program is Alleance® (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is SOPHiA GENETICS SA's next FDA catalyst?→
SOPHiA GENETICS SA's (SOPH) next tracked catalyst is a Phase 3 readout expected Q4 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track SOPH biotech catalysts?→
Add SOPH to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow SOPHiA GENETICS SA's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.